Exploring Why People With Type 2 Diabetes Do or Do Not Persist With Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Qualitative Study | Zendy

William H. Polonsky | Zendy; Cory Gamble | Zendy; Neeraj N. Iyer | Zendy; Mona L. Martin | Zendy; Carol Hamersky | Zendy

Open Access

Exploring Why People With Type 2 Diabetes Do or Do Not Persist With Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Qualitative Study

Author(s) -

William H. Polonsky,

Cory Gamble,

Neeraj N. Iyer,

Mona L. Martin,

Carol Hamersky

Publication year - 2021

Publication title -

diabetes spectrum

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.716

H-Index - 31

eISSN - 1944-7353

pISSN - 1040-9165

DOI - 10.2337/ds20-0025

Subject(s) - medicine , agonist , glucagon like peptide 1 receptor , discontinuation , type 2 diabetes , diabetes mellitus , receptor , pharmacology , endocrinology

Despite the demonstrated benefits of glucagon-like peptide 1 (GLP-1) receptor agonist therapy, adherence and persistence with this therapy is often challenging. The purpose of this study was to expand current understanding of patients' experiences, motivations, and challenges relevant to their persistence with GLP-1 receptor agonist therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research